Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence
The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Cannabis has long been perceived as a drug causing questionable dependence. Only recently has a clinically recognized withdrawal syndrome been described, thus laying the foundations for specific treatment evaluations. Six different pharmacotherapies have been studied in cannabis withdrawal. Of these, only oral tetrahydrocannabinol, and perhaps mirtazapine, have shown some promise in the specific treatment of withdrawal symptoms. In cannabis dependence, rimonabant, and perhaps buspiron, have shown promising results. Clinical trials of oral tetrahydrocannabinol were less convincing. Cognitive and behavioral therapies and motivational enhancement therapies have proven their efficacy in several randomized controlled trials. Brief therapies have also been associated with good compliance and efficacy. Combinations with voucher incentives in certain populations have been associated with improved treatment compliance and reduced cannabis use. Only two studies have analyzed the cost-efficacy of psychotherapies. It would seem that brief combined cognitive and behavioral therapies, and motivational enhancement therapies are the most cost effective. For the moment, it is uncertain whether the additional treatment costs associated with voucher incentives are proportional to the accrued abstinence duration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Caspi, A., Moffitt, T. E., Cannon, M., McClay, J., Murray, R., Harrington, H., Taylor, A., Arseneault, L., Williams, B., Braithwaite, A., et al. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.01.026 · Cited by 1,409
Anthony, J. C., Warner, L. A., & Kessler, R. C. (1994) · Experimental and Clinical Psychopharmacology · doi:10.1037/1064-1297.2.3.244 · Cited by 1,341
Comparison of extended versus brief treatments for marijuana use.
Stephens, R. S., Roffman, R. A., & Curtin, L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.5.898 · Cited by 711
A randomized controlled trial of brief cognitive–behavioral interventions for cannabis use disorder
Copeland, J., Swift, W., Roffman, R., & Stephens, R. (2001) · Journal of Substance Abuse Treatment · doi:10.1016/s0740-5472(01)00179-9 · Cited by 322
Brief treatments for cannabis dependence: Findings from a randomized multisite trial
Babor, T. F., & The Marijuana Treatment Project Research Group (2004) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.72.3.455 · Cited by 313
Budney, A. J., Moore, B. A., Rocha, H. L., & Higgins, S. T. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.4.2.307 · Cited by 290
Donovan, S. J., Stewart, J. W., Nunes, E. V., Quitkin, F. M., Parides, M., Daniel, W., Susser, E., & Klein, D. F. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.5.818 · Cited by 273
Carroll, K. M., Easton, C. J., Nich, C., Hunkele, K. A., Neavins, T. M., Sinha, R., Ford, H. L., Vitolo, S. A., Doebrick, C. A., & Rounsaville, B. J. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.5.955 · Cited by 214
Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms
Budney, A. J., Vandrey, R. G., Hughes, J. R., Moore, B. A., & Bahrenburg, B. (2007) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2006.04.014 · Cited by 180
Cited by
Nabiximols as an Agonist Replacement Therapy During Cannabis Withdrawal: A Randomized Clinical Trial
Allsop, D. J., Copeland, J., Lintzeris, N., Dunlop, A. J., Montebello, M., Sadler, C., Rivas, G. R., Holland, R. M., Muhleisen, P., Norberg, M. M., et al. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3947 · Cited by 266
Pharmacotherapies for cannabis dependence.
Marshall, K., Gowing, L., Ali, R., & Le Foll, B. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub2 · Cited by 156
Internet and computer based interventions for cannabis use: a meta-analysis
Tait, R. J., Spijkerman, R., & Riper, H. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.05.012 · Cited by 144
“A review by Benyamina et al. (2008) concluded that extended therapies which combined therapeutic approaches (i.”
BackgroundPharmacotherapies for cannabis dependence
Nielsen, S., Gowing, L., Sabioni, P., & Le Foll, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008940.pub3 · Cited by 96
Metadata
- Authors
- Benyamina, A., Lecacheux, M., Blecha, L., Reynaud, M., & Lukasiewcz, M.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2008-03
- Volume
- 8
- Issue
- 3
- Pages
- 479-491
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2140147844
- Cited by
- 44
- References
- 15
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. https://app.cochat.ai/papers/10.1586/14737175.8.3.479
- The paper
- Benyamina, A., Lecacheux, M., Blecha, L., Reynaud, M., & Lukasiewcz, M. (2008). Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence. Expert Review of Neurotherapeutics. https://doi.org/10.1586/14737175.8.3.479
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.